Trial Review

We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04179175




Registration number
NCT04179175
Ethics application status
Date submitted
25/11/2019
Date registered
27/11/2019
Date last updated
4/05/2021

Titles & IDs
Public title
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
Scientific title
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa
Secondary ID [1] 0 0
CAIN457M2301E1
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hidradenitis Suppurativa 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - secukinumab

Active Comparator: secukinumab 1 HiSCR Responder - HiSCR responder in core trial, secukinumab 300mg every 2 weeks

Active Comparator: secukinumab 2 HiSCR Responder - HiSCR responder in core trial, secukinumab 300mg every 4 weeks

Placebo Comparator: placebo 1 HiSCR Responder - HiSCR responder in core trial, placebo to secukinumab 300mg every 2 weeks

Placebo Comparator: placebo 2 HiSCR Responder - HiSCR responder in core trial, placebo to secukinumab 300 mg every 4 weeks

Active Comparator: HiSCR non-responders - non-responder to core trial treatment; secukinumab 300mg every 2 weeks


Treatment: Drugs: secukinumab
secukinumab 300mg every 2 or every 4 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
time to loss of response (LOR) in HiSCR reponders - Loss of response is defined as:
at least a 50% increase in abscess and/or nodules count (AN) compared to the average AN count from the 3 previous visits and the increase was at least of 3 AN from the average AN count of the 3 previous visits.
at least a 30% increase in AN compared to the average AN count from the 3 previous visits with an increase of at least 2 AN from the average count of the 3 previous visits or a further increase in the AN count of at least 2 AN .
Timepoint [1] 0 0
Weeks 52 - 104
Secondary outcome [1] 0 0
Cumulative rate of subjects who experience a flare in core HiScr responders - subjects who experience at least one flare by Week 104. flare is defined as at least a 25% increase in AN count with a minimum increase of 2 AN relative to baseline.
Timepoint [1] 0 0
Week 104
Secondary outcome [2] 0 0
subjects achieving NRS30 - HS-related skin pain; subjects achieving NRS30 at week 104, defined as at least a 30% reduction and at least one unit reduction from baseline in the subject's Global Assessment of Skin Pain
Timepoint [2] 0 0
Week 104

Eligibility
Key inclusion criteria
- written informed consent must be obtained before any assessment is performed

- subject must have completed the study treatment period (52 weeks) in the core studies
(AIN457M2301 or AIN457M2302)and have been receiving secukinumab treatment during
Treatment Period 2
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- protocol deviation in the core study which will prevent the meaningful analysis of the
extension study

- ongoing or planned use of prohibited HS or non-HS treatment

- participation in the extension could expose the subject to an undue safety risk

- current sever progressive or uncontrolled disease which renders the subject unsuitable
for the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/01/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
18/08/2026
Actual
Sample size
Target
856
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,QLD,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Phillip
Recruitment hospital [2] 0 0
Novartis Investigative Site - Benowa
Recruitment hospital [3] 0 0
Novartis Investigative Site - East Melbourne
Recruitment postcode(s) [1] 0 0
2606 - Phillip
Recruitment postcode(s) [2] 0 0
4217 - Benowa
Recruitment postcode(s) [3] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
Nebraska
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Virginia
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Capital Federal
Country [20] 0 0
Austria
State/province [20] 0 0
Linz
Country [21] 0 0
Austria
State/province [21] 0 0
Wien
Country [22] 0 0
Belgium
State/province [22] 0 0
Bruxelles
Country [23] 0 0
Belgium
State/province [23] 0 0
Gent
Country [24] 0 0
Belgium
State/province [24] 0 0
Liege
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Pleven
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Sofia
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Stara Zagora
Country [28] 0 0
Canada
State/province [28] 0 0
Ontario
Country [29] 0 0
Colombia
State/province [29] 0 0
Atlantico
Country [30] 0 0
Czechia
State/province [30] 0 0
Czech Republic
Country [31] 0 0
Czechia
State/province [31] 0 0
Prague 1
Country [32] 0 0
Czechia
State/province [32] 0 0
JIhlava
Country [33] 0 0
Czechia
State/province [33] 0 0
Plzen
Country [34] 0 0
France
State/province [34] 0 0
Haute Vienne
Country [35] 0 0
France
State/province [35] 0 0
Val De Marne
Country [36] 0 0
France
State/province [36] 0 0
Antony
Country [37] 0 0
France
State/province [37] 0 0
Bordeaux Cedex
Country [38] 0 0
France
State/province [38] 0 0
Brest
Country [39] 0 0
France
State/province [39] 0 0
Creteil
Country [40] 0 0
France
State/province [40] 0 0
Lyon
Country [41] 0 0
France
State/province [41] 0 0
Martigues
Country [42] 0 0
France
State/province [42] 0 0
Montpellier cedex 5
Country [43] 0 0
France
State/province [43] 0 0
Nantes Cedex 1
Country [44] 0 0
France
State/province [44] 0 0
Nice
Country [45] 0 0
France
State/province [45] 0 0
Paris Cedex 10
Country [46] 0 0
France
State/province [46] 0 0
Reims
Country [47] 0 0
France
State/province [47] 0 0
Rouen Cedex
Country [48] 0 0
France
State/province [48] 0 0
Saint Mande
Country [49] 0 0
France
State/province [49] 0 0
Saint-Etienne
Country [50] 0 0
France
State/province [50] 0 0
Toulouse
Country [51] 0 0
Germany
State/province [51] 0 0
Berlin
Country [52] 0 0
Germany
State/province [52] 0 0
Bielefeld
Country [53] 0 0
Germany
State/province [53] 0 0
Bochum
Country [54] 0 0
Germany
State/province [54] 0 0
Dessau Rosslau
Country [55] 0 0
Germany
State/province [55] 0 0
Erlangen
Country [56] 0 0
Germany
State/province [56] 0 0
Frankfurt
Country [57] 0 0
Germany
State/province [57] 0 0
Halle (Saale)
Country [58] 0 0
Germany
State/province [58] 0 0
Hamburg
Country [59] 0 0
Germany
State/province [59] 0 0
Heidelberg
Country [60] 0 0
Germany
State/province [60] 0 0
Langenau
Country [61] 0 0
Germany
State/province [61] 0 0
Memmingen
Country [62] 0 0
Germany
State/province [62] 0 0
Muenchen
Country [63] 0 0
Germany
State/province [63] 0 0
Muenster
Country [64] 0 0
Germany
State/province [64] 0 0
Potsdam
Country [65] 0 0
Germany
State/province [65] 0 0
Schwerin
Country [66] 0 0
Germany
State/province [66] 0 0
Wuerzburg
Country [67] 0 0
Greece
State/province [67] 0 0
GR
Country [68] 0 0
Greece
State/province [68] 0 0
Athens
Country [69] 0 0
Guatemala
State/province [69] 0 0
Guatemala City
Country [70] 0 0
Hungary
State/province [70] 0 0
Budapest
Country [71] 0 0
Hungary
State/province [71] 0 0
Debrecen
Country [72] 0 0
Hungary
State/province [72] 0 0
Kaposvar
Country [73] 0 0
Hungary
State/province [73] 0 0
Pecs
Country [74] 0 0
India
State/province [74] 0 0
Karnataka
Country [75] 0 0
India
State/province [75] 0 0
Maharashtra
Country [76] 0 0
Israel
State/province [76] 0 0
Jerusalem
Country [77] 0 0
Israel
State/province [77] 0 0
Petach Tikva
Country [78] 0 0
Israel
State/province [78] 0 0
Ramat Gan
Country [79] 0 0
Israel
State/province [79] 0 0
Tel Aviv
Country [80] 0 0
Italy
State/province [80] 0 0
AN
Country [81] 0 0
Italy
State/province [81] 0 0
FE
Country [82] 0 0
Italy
State/province [82] 0 0
FI
Country [83] 0 0
Italy
State/province [83] 0 0
PI
Country [84] 0 0
Italy
State/province [84] 0 0
RM
Country [85] 0 0
Italy
State/province [85] 0 0
Napoli
Country [86] 0 0
Japan
State/province [86] 0 0
Aichi
Country [87] 0 0
Japan
State/province [87] 0 0
Chiba
Country [88] 0 0
Japan
State/province [88] 0 0
Okinawa
Country [89] 0 0
Japan
State/province [89] 0 0
Saitama
Country [90] 0 0
Japan
State/province [90] 0 0
Tokyo
Country [91] 0 0
Korea, Republic of
State/province [91] 0 0
Seoul
Country [92] 0 0
Lebanon
State/province [92] 0 0
Saida
Country [93] 0 0
Lithuania
State/province [93] 0 0
LTU
Country [94] 0 0
Lithuania
State/province [94] 0 0
Vilniaus
Country [95] 0 0
Malaysia
State/province [95] 0 0
Wilayah Persekutuan
Country [96] 0 0
Malaysia
State/province [96] 0 0
Johor Bahru
Country [97] 0 0
Malaysia
State/province [97] 0 0
Penang
Country [98] 0 0
Mexico
State/province [98] 0 0
Jalisco
Country [99] 0 0
Mexico
State/province [99] 0 0
Nuevo Leon
Country [100] 0 0
Netherlands
State/province [100] 0 0
Bergen op Zoom
Country [101] 0 0
Philippines
State/province [101] 0 0
Las Pinas
Country [102] 0 0
Philippines
State/province [102] 0 0
Makati City
Country [103] 0 0
Poland
State/province [103] 0 0
Mazowian
Country [104] 0 0
Poland
State/province [104] 0 0
Lodz
Country [105] 0 0
Poland
State/province [105] 0 0
Ossy
Country [106] 0 0
Poland
State/province [106] 0 0
Rzeszow
Country [107] 0 0
Poland
State/province [107] 0 0
Warszawa
Country [108] 0 0
Poland
State/province [108] 0 0
Wroclaw
Country [109] 0 0
Portugal
State/province [109] 0 0
Lisboa
Country [110] 0 0
Portugal
State/province [110] 0 0
Porto
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Chelyabinsk
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Kazan
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Krasnodar
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Saint Petersburg
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Smolensk
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Yaroslavl
Country [117] 0 0
Singapore
State/province [117] 0 0
Singapore
Country [118] 0 0
Slovakia
State/province [118] 0 0
Slovak Republic
Country [119] 0 0
Slovakia
State/province [119] 0 0
Kosice
Country [120] 0 0
Slovakia
State/province [120] 0 0
Presov
Country [121] 0 0
South Africa
State/province [121] 0 0
Gauteng
Country [122] 0 0
Spain
State/province [122] 0 0
Andalucia
Country [123] 0 0
Spain
State/province [123] 0 0
Comunidad Valenciana
Country [124] 0 0
Spain
State/province [124] 0 0
Madrid
Country [125] 0 0
Spain
State/province [125] 0 0
Valencia
Country [126] 0 0
Spain
State/province [126] 0 0
Barcelona
Country [127] 0 0
Spain
State/province [127] 0 0
Granada
Country [128] 0 0
Spain
State/province [128] 0 0
Las Palmas de Gran Canaria
Country [129] 0 0
Spain
State/province [129] 0 0
Pontevedra
Country [130] 0 0
Switzerland
State/province [130] 0 0
Bern
Country [131] 0 0
Switzerland
State/province [131] 0 0
Lausanne
Country [132] 0 0
Taiwan
State/province [132] 0 0
Taipei
Country [133] 0 0
Taiwan
State/province [133] 0 0
Taoyuan
Country [134] 0 0
Turkey
State/province [134] 0 0
TUR
Country [135] 0 0
Turkey
State/province [135] 0 0
Altunizade
Country [136] 0 0
Turkey
State/province [136] 0 0
Antalya
Country [137] 0 0
Turkey
State/province [137] 0 0
Aydin
Country [138] 0 0
Turkey
State/province [138] 0 0
Talas / Kayseri
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Manchester
Country [140] 0 0
United Kingdom
State/province [140] 0 0
West Midlands
Country [141] 0 0
United Kingdom
State/province [141] 0 0
West Yorkshire
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Barnsley
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Bristol
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Exeter
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Harrogate
Country [146] 0 0
United Kingdom
State/province [146] 0 0
London
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Norwich
Country [148] 0 0
Vietnam
State/province [148] 0 0
Hanoi
Country [149] 0 0
Vietnam
State/province [149] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this extension study is to evaluate maintenance of HiSCR response at Week 104
in either continuous or interrupted therapy (using a randomized withdrawal period) of two
dose regimens and to assess long-term efficacy, safety and tolerability of secukinumab in
subjects with moderate to severe hidradenitis suppurativa completing either of the 2 Phase
III studies. This is an expanded access trial for the core trials AIN457M2301 (NCT03713619)
and AIN457M2302 (NCT03713619).
Trial website
https://clinicaltrials.gov/show/NCT04179175
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
1-888-669-6682
Fax 0 0
Email 0 0
novartis.email@novartis.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT04179175